S&P 500 7,443.28 -0.19% NASDAQ 25,508.07 -0.05% DOW 51,839.26 -0.59% R2K 2,942.43 -0.67% VIX 17.58 -5.74% US 10Y 4.60 +1.26% DXY 100.92 -0.07% GOLD 4,072.00 +1.54% CRUDE 81.62 -1.93% BITCOIN 66,275.53 +1.60%
Next Bullish Trade
Sign in
ALKS

Alkermes plc ALKS

$51.72 -1.00 (-1.90%)
Neutral · +0.42σ
+ Compare Open in Sniper

Price chart

Timeframe
Range
Fundamentals · free Click ▲ earnings markers (daily) for the day's move

Loading…

Latest bar · ALKS

Momentum reads · latest daily bar
Last
$51.72
-1.00 (-1.90%)
Mkt cap
$8.6B
Healthcare
RSI(14)
57.9
neutral
Stochastic %K
31.6
neutral
MFI(14)
46.7
neutral
ADX(14)
47.5
trending

Green means room to run, red means stretched — the reads re-read live as you switch the chart's timeframe. MFI(14) is a volume-weighted money-flow read: above 80 = overbought, below 20 = oversold.

Financial overlay · last 12 quarters

The story behind the price: three years of quarterly results laid over the chart, so you can see whether the stock has been following the business — or running ahead of it.

QuarterRevenue Net incomeOp income FCFNet margin Op margin
2026-03-31 $0.4B $-0.1B $-0.0B $-0.2B -16.9% -12.3%
2025-12-31 $0.4B $0.0B $0.1B $0.2B 12.8% 15.1%
2025-09-30 $0.4B $0.1B $0.1B $0.1B 21.0% 22.6%
2025-06-30 $0.4B $0.1B $0.1B $0.1B 22.3% 23.8%
2025-03-31 $0.3B $0.0B $0.0B $0.1B 7.3% 4.5%
2024-12-31 $nanB $nanB $nanB $nanB nan% nan%

Tip: toggle P/E, FCF, ROE, Gross margin and more on the chart above — every overlay is free.

Compare ALKS vs peers

Line ALKS up against up to 4 peers (5 tickers total) across ~30 metrics and get one weighted 0-100 verdict — best in green, worst in red. Peers also overlay on the chart above as rebased % lines, or flip the chart to the 2×2 grid for side-by-side mini charts.

Comparing ALKS no peers yet — add up to 4 below
Sector peers + LLY + UNH + JNJ + MRK + ABBV + PFE
Popular + AAPL + MSFT + NVDA + AMZN + GOOG + META + TSLA + AVGO
Matchups NVDA · AMD · AVGO · SMCI · MU AAPL · MSFT · GOOG · META · AMZN JPM · GS · MS · BAC · C TSLA · RIVN · LCID · GM · F XOM · CVX · OXY · COP

Add tickers to compare with ALKS

~30 metrics across Snapshot, OdysseyHQ zone, Valuation, Growth, Quality, Technicals, Sentiment, and Risk — with a weighted score and a one-line read on each.

Earnings replay · last 20 reports

How this stock actually behaves on report day: each past earnings print with the beat-or-miss and the next-day move — a track record for handicapping the next one.

DateEPS actual EPS estSurprise Next-day
2026-05-05 0.38 -0.04 +1053.0% -2.6%
2026-02-25 0.48 0.45 +7.7% -1.0%
2025-10-28 0.65 0.39 +68.5% +1.4%
2025-07-29 0.68 0.40 +71.1% +3.4%
2025-05-01 0.29 0.24 +18.9% +3.9%
2025-02-12 1.05 0.76 +37.6% +7.5%
2024-10-24 0.73 0.71 +2.4% -2.8%
2024-07-24 0.70 0.71 -0.8% +5.8%
2024-05-01 0.43 0.58 -26.2% -0.6%
2024-02-15 0.22 0.46 -52.0% -1.2%
2023-10-25 0.64 0.43 +50.2% +5.3%
2023-07-26 0.55 0.64 -13.8% +0.8%
2023-04-26 0.01 -0.01 +180.0% -0.1%
2023-02-16 0.14 0.05 +210.8% -0.4%
2022-11-02 0.02 0.03 -32.8% +0.3%
2022-07-27 0.06 0.05 +26.7% -4.6%
2022-04-27 0.12 0.03 +380.0% -1.9%
2022-02-16 0.23 0.13 +72.5% -5.4%
2021-10-27 0.14 0.10 +46.3% +1.0%
2021-07-28 0.30 0.12 +142.4% -0.8%

Earnings markers are overlaid on the daily price chart above. Click a ▲ marker for that day's move.

Peer comparison · Healthcare

Context check: the same key numbers for the closest Healthcare names side by side, so you can tell whether this stock is the standout or just moving with its group.

Ticker ⇅ Mkt cap ⇅ P/E ⇅ Fwd P/E ⇅ P/S ⇅ EV/EBITDA ⇅ P/B ⇅ Gross M ⇅ Rev gr ⇅ EPS gr ⇅ FCF yld ⇅
ALKS ★ $9B 58.8 31.6 5.5 34.8 4.9 87.4% 28.2% — 1.63%
LLY $1,023B 41.8 25.5 14.2 29.3 32.8 82.8% 55.5% 169.9% 0.90%
UNH $383B 32.1 18.8 0.9 17.5 3.9 19.5% 0.4% 61.5% 5.95%
JNJ $599B 29.3 19.4 6.1 18.1 7.4 68.1% 6.6% -1.0% —
MRK $307B 36.0 12.9 4.7 11.9 6.7 76.7% 4.9% — 4.57%
ABBV $448B 124.8 15.6 7.1 17.1 -67.3 72.0% 12.4% -46.2% 4.65%
PFE $141B 19.2 8.7 2.2 7.6 1.6 74.8% 5.4% -10.1% 8.77%
TMO $196B 29.2 19.3 4.3 20.9 3.8 40.9% 6.2% 11.3% 2.82%

Auto-seeded from sector. Click any ticker to switch.

Ownership

Who holds the stock and what they've been doing lately — big funds on the left, executives' own buys and sells on the right. Insider buying is the rarer, louder signal.

Top institutional holders

Top-10 concentration: 54.22%

HolderShares% out
Blackrock Inc. 28,314,410 16.99%
Baker Bros. Advisors, LP 10,012,267 6.01%
Vanguard Portfolio Management LLC 9,511,112 5.71%
State Street Corporation 9,465,286 5.68%
Vanguard Capital Management LLC 7,427,397 4.46%
Renaissance Technologies, LLC 6,160,428 3.70%
American Century Companies Inc 6,072,103 3.64%
Price (T.Rowe) Associates Inc 4,664,576 2.80%
Dimensional Fund Advisors LP 4,522,378 2.71%
Commodore Capital Lp 4,200,000 2.52%

Insider activity · 90d

0 buys / 7 sells · ratio 0.0 · Finnhub

  • Gaffin David Joseph SELL 227,490 @ $54.03
  • Hopkinson Craig C. M 1,356
  • Hopkinson Craig C. SELL 73,389 @ $52.13
  • Hopkinson Craig C. SELL 74,089 @ $51.46
  • Hopkinson Craig C. M 82,389 @ $19.34
  • Wright Christopher I SELL 25,680 @ $45.10
  • Gaffin David Joseph SELL 229,524 @ $43.05
  • Hopkinson Craig C. M 6,356
  • Hopkinson Craig C. SELL 77,389 @ $41.67
  • Hopkinson Craig C. M 86,389 @ $19.34

Analyst estimates

Finnhub

What Wall Street expects next: the consensus forecasts for the coming quarters. The market usually reacts to results versus these numbers, not the raw results themselves.

Low
$34.0
Mean
$52.64706
High
$65.0
Analysts
17
Recommendation distribution · period 2026-07-01
6
13
3
1
Revision trend (2026-04-01 → 2026-07-01): net 20 → 18 -2 (net = strong_buy+buy − sell−strong_sell)

SEC filings

The company's own paperwork, straight from the regulator — annual and quarterly reports, big announcements and insider trades. The primary source behind every headline.

FormFiled DescriptionAction
8-K 2026-07-08 8-K view ·
4 2026-07-06 PRIMARY DOCUMENT view ·
4 2026-07-01 PRIMARY DOCUMENT view ·
8-K 2026-06-15 8-K view ·
4 2026-06-12 PRIMARY DOCUMENT view ·
4 2026-06-04 PRIMARY DOCUMENT view ·
4 2026-06-01 PRIMARY DOCUMENT view ·
4 2026-05-29 PRIMARY DOCUMENT view ·
4 2026-05-22 PRIMARY DOCUMENT view ·
4 2026-05-22 PRIMARY DOCUMENT view ·
4 2026-05-22 PRIMARY DOCUMENT view ·
4 2026-05-22 PRIMARY DOCUMENT view ·
4 2026-05-22 PRIMARY DOCUMENT view ·
4 2026-05-22 PRIMARY DOCUMENT view ·
4 2026-05-22 PRIMARY DOCUMENT view ·
4 2026-05-22 PRIMARY DOCUMENT view ·
8-K 2026-05-20 8-K view ·
8-K 2026-05-12 8-K view ·
10-Q 2026-05-05 10-Q view ·
8-K 2026-05-05 8-K view ·
4 2026-05-04 PRIMARY DOCUMENT view ·
4 2026-05-01 PRIMARY DOCUMENT view ·
4 2026-04-13 PRIMARY DOCUMENT view ·
4 2026-04-06 PRIMARY DOCUMENT view ·
DEF 14A 2026-04-06 DEF 14A view ·
4 2026-04-01 PRIMARY DOCUMENT view ·
4 2026-03-04 PRIMARY DOCUMENT view ·
4 2026-03-04 PRIMARY DOCUMENT view ·
4 2026-03-04 PRIMARY DOCUMENT view ·
4 2026-03-04 PRIMARY DOCUMENT view ·
4 2026-03-04 PRIMARY DOCUMENT view ·
4 2026-03-04 PRIMARY DOCUMENT view ·
4 2026-03-04 PRIMARY DOCUMENT view ·
4 2026-02-27 PRIMARY DOCUMENT view ·
4 2026-02-27 PRIMARY DOCUMENT view ·
4 2026-02-27 PRIMARY DOCUMENT view ·
4 2026-02-27 PRIMARY DOCUMENT view ·
4 2026-02-27 PRIMARY DOCUMENT view ·
4 2026-02-25 PRIMARY DOCUMENT view ·
4 2026-02-25 PRIMARY DOCUMENT view ·
4 2026-02-25 PRIMARY DOCUMENT view ·
4 2026-02-25 PRIMARY DOCUMENT view ·
4 2026-02-25 PRIMARY DOCUMENT view ·
8-K 2026-02-25 8-K view ·
10-K 2026-02-25 10-K view ·
8-K 2026-02-25 8-K view ·
4 2026-02-20 PRIMARY DOCUMENT view ·
4 2026-02-20 PRIMARY DOCUMENT view ·
4 2026-02-20 PRIMARY DOCUMENT view ·
4 2026-02-20 PRIMARY DOCUMENT view ·
4 2026-02-20 PRIMARY DOCUMENT view ·
8-K 2026-02-12 8-K view ·
4 2026-02-06 PRIMARY DOCUMENT view ·
4 2026-02-06 PRIMARY DOCUMENT view ·
4 2026-02-06 PRIMARY DOCUMENT view ·
4 2026-02-06 PRIMARY DOCUMENT view ·
4 2026-02-06 PRIMARY DOCUMENT view ·
4 2026-02-02 PRIMARY DOCUMENT view ·
4 2026-02-02 PRIMARY DOCUMENT view ·
8-K 2026-01-12 8-K view ·

About ALKS

Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmace…

Options picks · ALKS

ITM + OTM ideas from the latest scan

Loading…

Congress trades · ALKS

STOCK Act disclosures

Loading…

SEC filings & insiders · ALKS

EDGAR · live

Loading…

Holders · ALKS

Institutions & insider activity

Loading…